Top > Search of International Patents > Human abzyme

Human abzyme UPDATE_EN

Foreign code F170009200
File No. AF12-05EP4
Posted date Sep 12, 2017
Country EPO
Application number 15155990
Gazette No. 2894222
Gazette No. 2894222
Date of filing Feb 21, 2011
Gazette Date Jul 15, 2015
Gazette Date Aug 22, 2018
International application number JP2011053752
International publication number WO2011102517
Date of international filing Feb 21, 2011
Date of international publication Aug 25, 2011
Priority data
  • P2010-034998 (Feb 19, 2010) JP
  • P2010-035021 (Feb 19, 2010) JP
  • P2010-092461 (Apr 13, 2010) JP
  • 20110744803 (Feb 21, 2011) EP
  • 2011JP53752 (Feb 21, 2011) WO
Title Human abzyme UPDATE_EN
Abstract The present invention provides a human abzyme containing a human antibody º light chain.
Outline of related art and contending technology Background Art
The inventers of the present invention have conducted various and ingenious researches into abzymes (for example, refer to Patent Literature 1). Conventionally, abzymes which include fully human sequence have been obtained only from Bence Jones protein (BJP) that is obtained from multiple myeloma patients. The number of multiple myeloma patients is small, and besides, only a few BJP contain enzyme activity, so that it has been difficult to obtain human abzymes. However, side effects of human abzymes for a human body are expected to be less. Therefore, domestic and international pharmaceutical companies etc. have longed for useful human abzymes to be developed.
By the way, rabies is an infectious disease which still imposes a heavy disease burden in developing countries and a fatal disease with 100% of mortality rate at a time of the onset of rabies. There is no effective treatment for rabies at this time other than administration of vaccine to prevent rabies from developing after exposure to rabies viruses. Therefore, development of a treatment for rabies from a new viewpoint is desired.
The international patent application published under the reference WO2004/106375 discloses human rabies-neutralizing antibodies.
Also, influenza viruses are so diverse in their antigenicity that influenza spreads wide and causes serious damage. Therefore, development of a treatment for influenza from a new viewpoint is desired.
Citation List
Patent Literatures
Patent Literature 1
Japanese Patent Application Publication, Tokukai No. 2006-197930 (Publication Date: August 3, 2006)
Patent Literature 2
Japanese Patent Application Publication, Tokukai No. 2004-97211 (Publication Date: April 2, 2004)

Scope of claims [claim1]
1. A human abzyme being a human antibody κ light chain against rabies virus and having a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 50.

[claim2]
2. The human abzyme as set forth in Claim 1, wherein the human abzyme has an anti-influenza virus activity and nucleolytic activity.

[claim3]
3. An antiviral agent for use in the prevention of and/or treatment of an influenza virus infectious disease comprising a human abzyme recited in claim 1 or 2.
  • Applicant
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • Inventor
  • Uda, Taizo
  • Hifumi, Emi
  • Nioshizono, Akira
  • Arakawa, Mitsue
IPC(International Patent Classification)
Specified countries Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Reference ( R and D project ) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close